Európai Unió - magyar - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioödéma, örökletes - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

Európai Unió - magyar - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianémiás készítmények - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Európai Unió - magyar - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - daganatellenes szerek - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Európai Unió - magyar - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - szapropterin dihidroklorid - phenylketonurias - egyéb táplálkozási traktus pedig anyagcsere termékek, - sapropterin dipharma is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment. sapropterin dipharma is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.

Európai Unió - magyar - EMA (European Medicines Agency)

novartis europharm limited  - capmatinib dihydrochloride monohydrate - karcinóma, nem kissejtes tüdő - daganatellenes szerek - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.

Európai Unió - magyar - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunszuppresszánsok - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Európai Unió - magyar - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - egyéb idegrendszeri gyógyszerek - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Európai Unió - magyar - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - pegunigalsidase alfa - fabry-betegség - egyéb táplálkozási traktus pedig anyagcsere termékek, - elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of fabry disease (deficiency of alpha-galactosidase).

Magyarország - magyar - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

g.r. kereskedelmi és szolgáltató bt. - trimetoprim, szulfadimetoxin-nátrium - külsoleges oldat - sulfadimethoxine and trimethoprim - kutya

Magyarország - magyar - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

bionorica se - növényi kivonatok -